why choose us

First received: August 24, 2023

Clinical Trial: GLP-1RAs) and SGLT2is Combination Therapy and MACEs in Patients with Type 2 Diabetes.

Study Status: COMPLETED

Recruit Status: COMPLETED

Condition: Diabetes Mellitus, Type 2

Study Type: OBSERVATIONAL


Official Title: Glucagon-like Peptide-1 Receptor Agonists (GLP-1RAs) and Sodium-glucose Cotransporter-2 Inhibitors (SGLT2is) Combination Therapy and Major Adverse Cardiovascular Events After Acute Myocardial Infarcti

Brief Summary: Management of type 2 diabetes mellitus (T2DM) has evolved from a glucocentric to a cardiometabolic approach.Both glucagon-like peptide-1 receptor agonists (GLP-1RAs) and sodium-glucose cotransporter-2 inhibitors (SGLT2is) reduce cardiovascular and kidney outcomes in T2DM patients with a low hypoglycemia risk.The T2DM di per se still carries a higher risk of mortality and major cardiovascular complications, doubling the case fatality rate.Tacking that GLP-1RAs and SGLT2is have different mechanisms of action,…

Read more